FMS
Fresenius Medical Care AG
Next earnings Aug 4, 2026 · consensus $1.04 EPS, $4.80B rev
$23.53
▲ +3.66%$23.53▼ -13.23%
over 1Y
L $19.41H $27.66
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.7%
1W+1.2%
1M+14.5%
3M+9.2%
YTD+4.1%
1Y-13.2%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 26 analysts
Hold
Strong net margin (22.3%).
Revenue (FY2013) $4.97B · FY2013
The read
Quality fundamentals and an attractive price line up (~38% below fair value) — the rarer case where both the business and the entry look good.
Fresenius Medical Care AG shows $4.97B in FY2013 revenue, a 22.3% net margin, and 10.3% ROE.
Supporting the case: strong net margin (22.3%); undemanding valuation (P/E 6.5).
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 10:31 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Financials · annual, by fiscal year
| Line item | FY09 | FY10 | FY11 | FY12 | FY13 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $4.97B |
| Gross profit | $3.83B | $3.84B | $4.15B | $4.60B | $4.74B |
| Operating income | $1.76B | $1.92B | $2.07B | $2.22B | $2.26B |
| Net income | $891M | $979M | $1.07B | $1.19B | $1.11B |
| Diluted EPS | $2.99 | $3.24 | $3.51 | $3.87 | $3.65 |
| Net margin | — | — | — | — | 22.3% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$19.7B
EV / EBITDA6.8
EV / Sales4.0
EV / FCF15.3
P / FCF9.8
PEG (trailing)—
Earnings yield8.8%
FCF yield10.2%
Quality & risk
ROIC (est.)9.6%
Free cash flow$1.29B
Total debt$7.81B
Net cash-$7.06B
Altman Z-Score1.55 distress
Piotroski F-Score5/7
Capital returns
Buyback yield—
Dividend yield (est.)2.3%
Shareholder yield2.3%
Shares Δ YoY-4.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗11-KPeriod ending 2025-12-312026-06-29open ↗6-KPeriod ending 2026-05-282026-05-28open ↗SDFiling2026-05-28open ↗6-KPeriod ending 2026-05-262026-05-26open ↗6-KPeriod ending 2026-03-312026-05-05open ↗6-KPeriod ending 2026-05-052026-05-05open ↗6-KPeriod ending 2026-04-142026-04-14open ↗3Period ending 2026-03-182026-03-18open ↗6-KPeriod ending 2026-02-242026-02-24open ↗IRANNOTICEFiling2026-02-24open ↗20-FPeriod ending 2025-12-312026-02-24open ↗6-KPeriod ending 2026-02-242026-02-24open ↗
Frequently asked
- Is Fresenius Medical Care AG (FMS) a buy?
- FMS currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Strong net margin (22.3%).
- What is FMS's fair value?
- A Modified-Graham model based on FMS's SEC fundamentals estimates a fair value of about $32.58. It is an estimate from reported earnings, not a price target.
- Is FMS overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, FMS currently appears undervalued relative to its SEC-grounded earnings power.
- What is Fresenius Medical Care AG's quality score?
- FMS scores 68.76827495049466/100 (grade B-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001333141, latest 11-K filed 2026-06-29) · EODHD · as of 6/21/2026, 2:31:48 PM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.